Indication
Long COVID-19
7 clinical trials
7 products
1 drug
Clinical trial
Pilot Study Into Low Dose Naltrexone (LDN) and Nicotinamide Adenine Dinucleotide (NAD+) for Treatment of Patients With Post-COVID-19 Syndrome (Long-COVID19)Status: Completed, Estimated PCD: 2023-01-23
Product
NaltrexoneClinical trial
RECOVER-AUTONOMIC: A Platform Protocol for Evaluation of Interventions for Autonomic Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)Status: , Estimated PCD: 2025-12-01
Product
IVIGProduct
IVIG PlaceboProduct
IvabradineClinical trial
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19: a Randomized, Double-blind, Parallel-controlled StudyStatus: Withdrawn, Estimated PCD: 2023-12-01
Product
UC-MSCsClinical trial
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Larazotide (AT1001) for the Treatment of Long COVID in Children and Young AdultsStatus: Recruiting, Estimated PCD: 2025-03-31
Product
LarazotideDrug
VarlilumabClinical trial
RECOVER-AUTONOMIC (IVIG): Randomized Trial of the Effect of IVIG Versus Placebo on Long COVID SymptomsStatus: , Estimated PCD: 2025-12-01
Clinical trial
RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)Status: , Estimated PCD: 2025-07-01
Product
PaxlovidClinical trial
RECOVER-AUTONOMIC (Ivabradine): Randomized Trial of the Effect of Ivabradine Versus Placebo on Long COVID SymptomsStatus: , Estimated PCD: 2025-12-01